Nov 01, 2022 / 03:00PM GMT
Operator
Good day, and thank you for standing by, and welcome to today's conference call. I would now like to hand the conference over to Alnylam Pharmaceuticals. Please go ahead.
Joshua Brodsky - Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications
Thank you. Good morning, everyone, and thanks for joining us for this RNAi roundtable. Today, we'll be discussing progress with the delivery of RNAi therapeutics to the central nervous system and reviewing our ALN-APP program, which is in development for the treatment of Alzheimer's disease and cerebral amyloid angiopathy. I'm Josh Brodsky, Senior Director of Investor Relations and Corporate Communications at Alnylam. With me today are Eric Green, Senior Vice President of Development Programs, Kirk Brown, Senior Director of Research for the CNS program; and Tim Mooney, Director and Program Lead for the ALN-APP program.
Today's RNAi roundtable is part of a series of roundtable webinars that we've been hosting to review progress across our various programs and R&D efforts. Previous
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: CNS Delivery and ALN-APP, in Development for the Treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot